pharmaphorum

AUGUST 25, 2022

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).

FDA 92

FDA Marketing Safety Patients 92

pharmaphorum

AUGUST 21, 2022

NMDA antagonist dextromethorphan is an ingredient found in cough syrups, while bupropion is an established antidepressant that was originally developed by GSK and sold as Wellbutrin. In this product, bupropion is designed to increase levels of dextromethorphan in the blood and extend its half-life.

FDA 87

FDA Marketing Pharma Sales 87

pharmaphorum

JULY 25, 2022

” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel). .”

Medicine 52

Medicine FDA Recruitment Patients 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Medicine 52

pharmaphorum

NOVEMBER 28, 2022

Substra is the software that powered the MELLODDY platform, a collaboration in which Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data — but not with each other directly, nor with Owkin.

Training 72

Training Medical Pharma Healthcare 72